Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies

Cephalalgia

Volumn 19, Issue 9, 1999, Pages 769-778

  Dahlof C ^a  

^a Gothenburg Migraine Clinic   (Sweden)

Author keywords

Clinical trials; Efficacy; Migraine; Nasal spray; Sumatriptan; Tolerability

Indexed keywords

NOSE SPRAY; PLACEBO; SUMATRIPTAN;

AQUEOUS SOLUTION; CLINICAL PROTOCOL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; MIGRAINE; REVIEW; TASTE DISORDER;

EID: 0032708564     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1999.1909769.x     Document Type: Review

References (19)

1. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
2. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache 1998;38:184-90
3. Pilgrim AJ, Blakeborough P. The clinical efficacy of sumatriptan in the acute treatment of migraine. Rev Contemp Pharmacother 1994;5:295-309
4. Lloyd K. The clinical profile of sumatriptan: Safety and tolerability. Eur Neurol 1994;34 Suppl 2:40-3
5. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:332-8
6. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 1994;241:463-9
7. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurol 1997;49:1225-30
8. Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 1998;7:234-40
9. Becker WJ, on behalf of the study group. A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, editors. Headache Treatment: Trial Methodology and New Drugs. Philadelphia: Lippincott-Raven, 1997
10. Glaxo Study No. S2B-T50. Data on file with Glaxo Wellcome Research and Development
11. Glaxo Study No. S2B-T60. Data on file with Glaxo Wellcome Research and Development
12. Glaxo Study No. S2B-T51. Data on file with Glaxo Wellcome Research and Development
13. Glaxo Study No. S2CM12. Data on file with Glaxo Wellcome Research and Development
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl:1-96
15. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia 1998;18:532-8
16. Ashford F., Salonen R, Saiers J, Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998;18:273-7
17. Cady RK, Wendt JK, Kerchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
18. Dahlof C, Boes-Hansen S, Cederberg C-G, Hardebo J-E, Henriksson A. How does sumatriptan nasal spray perform in clinical practice? Cephalalgia 1998;18:278-82
19. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998;6:99-104